LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
Paul Nathan(Mount Vernon Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Pier Francesco Ferrucci(MultiMedica), Keith T. Flaherty(Cancer Research Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), T Haas(Novartis (United States)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Aisha Masood(Novartis (United States)), Eduard Gasal, S. Green(Novartis (Switzerland)), Paul Lorigan(Manchester Academic Health Science Centre), Georgina V. Long(The University of Sydney), О. В. Леонов(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Antoni Ribas(University of California, Los Angeles), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), Mario Mandalà(University of Perugia), Hussain Tawbi(The University of Texas MD Anderson Cancer Center), Jan C. Brase(Novartis (Switzerland))
Cited by 68
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k